Denali Therapeutics Inc. (DNLI)
NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
At close: 04:00PM EDT
After hours:
| Previous close | 27.96 |
| Open | 28.00 |
| Bid | 30.76 x 100 |
| Ask | 30.86 x 100 |
| Day's range | 28.00 - 30.99 |
| 52-week range | 14.56 - 31.00 |
| Volume | |
| Avg. volume | 1,102,645 |
| Market cap | 4.405B |
| Beta (5Y monthly) | 1.37 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Zacks
Why Is Kymera Therapeutics (KYMR) Up 10.9% Since Last Earnings Report?
Kymera Therapeutics (KYMR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- Zacks
Myriad (MYGN) Down 4.8% Since Last Earnings Report: Can It Rebound?
Myriad (MYGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- Zacks
Denali Plans to File for Accelerated Approval of Hunter Syndrome Drug
DNLI's recent meeting with the FDA was successful and provides the path to file for accelerated approval of tividenofusp alfa for the treatment of MPS II and its subsequent conversion to full approval.
© 2024 Yahoo. All rights reserved.